Quantcast
Last updated on April 25, 2014 at 5:24 EDT

Latest Lupin Pharmaceuticals Inc. Stories

2014-03-21 12:24:25

MUMBAI, India and BALTIMORE, March 21, 2014 /PRNewswire/ -- Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary, Lupin Pharmaceuticals Inc. has launched its Niacin Extended-Release Tablets USP, 500 mg, 750 mg, 1000 mg strengths having received final approval from the United States Food and Drug Administration (FDA) yesterday. Lupin's Niacin Extended-Release Tablets USP, 500 mg, 750 mg, 1000 mg strengths are the AB-rated generic...

2013-12-18 12:25:41

MUMBAI and BALTIMORE, December 18, 2013 /PRNewswire/ -- Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary Lupin Pharmaceuticals Inc. has launched its Abacavir Sulfate, Lamivudine, and Zidovudine Tablets, 300 mg (base) / 150 mg / 300 mg in the US after the US District Court for the District of Delaware ruled that the Lupin's generic version of Trizivir(R) did not infringe on patents. Lupin had earlier received approval for the same. Lupin's...

2013-12-12 12:27:32

MUMBAI, India and BALTIMORE, December 12, 2013 /PRNewswire/ -- Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary, Lupin Pharmaceuticals, Inc. (LPI) has launched its Duloxetine Hydrochloride Delayed-release (HCl DR) Capsules 20 mg, 30 mg and 60 mg strengths. The Company received final approval to market its Duloxetine HCl DR Capsules USP, 20 mg, 30 mg, 40 mg and 60 mg strengths from the United States Food and Drugs Administration (FDA) yesterday....

2013-11-11 08:27:44

MUMBAI and BALTIMORE, November 11, 2013 /PRNewswire/ -- Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary, Lupin Pharmaceuticals, Inc. (LPI) has launched its generic Rabeprazole Sodium delayed-release tablets, 20mg. Lupin had earlier received final approval from the US FDA for the same. Lupin's Rabeprazole Sodium delayed-release tablets, 20mg, are the generic equivalent of Eisai Inc.'s Aciphex(R) delayed-release tablets, 20mg, and are indicated...

2013-10-22 12:29:10

MUMBAI, India and BALTIMORE, October 22, 2013 /PRNewswire/ -- Pharma Major Lupin Limited (Lupin) announced today that it has received final approval for its supplemental New Drug Application (sNDA) for Antara(R) (Fenofibrate) capsules, 30 mg & 90 mg strengths from the United States Food and Drug Administration (FDA). Lupin Pharmaceuticals Inc. (LPI), the company's US subsidiary, will commence marketing the product shortly. LPI currently markets and promotes Antara(R)...

2013-10-03 12:25:56

MUMBAI, India and BALTIMORE, October 3, 2013 /PRNewswire/ -- Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary, Lupin Pharmaceuticals, Inc. (LPI), has launched its generic Gatifloxacin Ophthalmic Solution, 0.5%. Lupin had earlier received final approval from the United States Food and Drugs Administration (US FDA) to market a generic version of Allergan Inc.'s Zymaxid(TM) Ophthalmic Solution, 0.5%. Lupin's Gatifloxacin Ophthalmic solution 0.5% is...

2013-09-23 12:26:17

Inks Strategic Agreement to Promote Locoid® Lotion to US Pediatricians MUMBAI, India and BALTIMORE, September 23, 2013 /PRNewswire/ -- Pharmaceutical Major, Lupin Ltd. and its US subsidiary, Lupin Pharmaceuticals Inc. (collectively Lupin) announced today that it has signed a strategic co-promotion agreement with US based Onset Dermatologics, LLC ("Onset") that grants Lupin exclusive rights to promote Onset's Locoid(R) Lotion (hydrocortisone butyrate 0.1%) to Pediatricians in...

2013-08-07 12:27:36

MUMBAI and BALTIMORE, August 7, 2013 /PRNewswire/ -- Announces Acquisition of Exclusive US Rights to Alinia(R) for Oral Suspension Pharmaceutical Major, Lupin Ltd. and its US subsidiary, Lupin Pharmaceuticals Inc. (collectively Lupin) announced today that it has signed a strategic licensing agreement with US pharmaceutical company Romark Laboratories, L.C. (Romark) which grants Lupin exclusive rights to promote, distribute and market Alinia(R) (nitazoxanide) for Oral...

2013-08-07 12:26:28

Lupin Acquires Exclusive License to Promote and Distribute Alinia for Oral Suspension in the United States using its Pediatric-Focused Sales Force TAMPA, Fla., Aug. 7, 2013 /PRNewswire/ -- Romark Laboratories announced that it has entered into a strategic agreement with Lupin Limited and its subsidiaries (collectively Lupin) designed to expand promotion and distribution efforts related to its Alinia(®) (nitazoxanide) for Oral Suspension, 100 mg/5 mL. Under the agreement, Lupin...

2013-07-31 12:27:23

MUMBAI and BALTIMORE, July 31, 2013 /PRNewswire/ -- elsPharma Major Lupin Limited announced today that its U.S. subsidiary, Lupin Pharmaceuticals, Inc. (LPI) has received tentative approval for its Armodafinil Tablets, 50 mg, 100 mg, 150 mg, 200 mg and 250 mg strengths as well as another tentative approval for its Doxycycline Capsules, 40 mg (30 mg Immediate-release and 10 mg Delayed-release) from the United States Food and Drugs Administration (FDA). Lupin's...